Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

WHO says eradicating malaria ‘can be done’, but first aim is to control it

The World Health Organization said eradicating malaria is biologically feasible and a lofty aim, but the focus for now should be getting the funds, tools and political will to control the mosquito-borne disease.

Read More »

Novartis executive sold shares before drug data manipulation made public

An unnamed Novartis executive sold 925,400 Swiss francs ($946,000) worth of shares less than three weeks before the U.S. Food and Drug Administration announced data from tests of the company’s gene therapy Zolgensma had been manipulated.

Read More »

Liver disease related to obesity and diabetes rising in U.S.

The only liver disease becoming more widespread in the U.S. is one driven by obesity and diabetes – NAFLD – even as other liver disorder types linked to drinking or hepatitis become less common.

Read More »

Novartis names new head of U.S. drugs business

Novartis named company veteran Victor Bulto as head of the Swiss drugmaker’s U.S. pharmaceuticals business, effective Sept. 1, 2019.

Read More »

U.S. budget deficit widens; spending up on health, military

The U.S. government’s deficit widened to $120 billion in July 2019, fueled by increases in spending on health care and the military, according to data released by the Treasury Department.

Read More »

Senators Urge FDA to Take Action Against AveXis

Days after the U.S. FDA revealed data manipulation was involved in the early studies of Novartis’ multi-million dollar gene therapy for SMA, U.S. Senate members demanded the regulatory agency take action against AveXis, the company that developed Zolgensma.

Read More »

One year after launch: Harness the power of sales data to maximize commercial success

During the year following the launch of a new product, a good commercial operations team should accumulate an abundance of helpful sales-related data. Analyzed properly, that data can help executives make better decisions and improve the product’s chances for long-term success. The challenge is: Where to start? How can the commercial team use sales data to better target physicians and better direct the sales force?

Read More »

Roche test showed Tecentriq helped vs bladder cancer

Roche Holding’s Tecentriq drug combined with platinum-based chemotherapy reduced the risk of the disease worsening or death in patients with advanced bladder cancer.

Read More »

Merck’s Keytruda Approved for Esophageal Cancer

The U.S. Food and Drug Administration approved the anti-PD-1 therapy Keytruda as a monotherapy for patients with recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus whose tumors express PD-L1 with disease progression after one or more previous lines of systemic therapy.

Read More »

FDA Advisory Committee Cancels Review of Intra-Cellular’s Schizophrenia Drug

Intra-Cellular Therapies shares fell after the company announced that the FDA canceled the advisory committee meeting to discuss the New Drug Application for the schizophrenia drug lumateperone.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!


Ad Right Bottom